CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

maridebart cafraglutide

Peptideexperimental

Clinical trial activity

17 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
9
Phase 3
7
Phase 4
0

Earliest trial started Aug 7, 2020 (NCT04478708)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07226765Phase 3Dec 17, 2025Amgen
NCT07225686Phase 3Dec 17, 2025Amgen
NCT07229157Phase 1Oct 22, 2025Amgen
NCT07226778Phase 1Oct 10, 2025Amgen
NCT07160257Phase 1Aug 5, 2025Amgen
NCT07037433Phase 3Jul 25, 2025Amgen
NCT07037459Phase 3Jun 25, 2025Amgen
NCT06987695Phase 3Jun 13, 2025Amgen
NCT06858878Phase 3Mar 17, 2025Amgen
NCT06858839Phase 3Mar 17, 2025Amgen
NCT07310563Phase 1Dec 10, 2024Amgen
NCT06660173Phase 2Nov 21, 2024Amgen
NCT06976372Phase 1Aug 20, 2024Amgen
NCT06352892Phase 1Apr 25, 2024Amgen
NCT05669599Phase 2Jan 18, 2023Amgen
NCT05056246Phase 1Sep 28, 2021Amgen
NCT04478708Phase 1Aug 7, 2020Amgen
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AmgenFor profit171732020
1 organizations
Page 1 / 1